These hot papers were published in the past two years and received enough citations in July/August 2025 to place them in the top 0.1% of papers in different academic fields.
1.
El-Saadony, M. T.,
Saad, A. M.,
Alkafaas, S. S.,
Dladla, M.,
Ghosh, S.,
Elkafas, S. S.,
Hafez, W.,
Ezzat, S. M.,
Khedr, S. A.,
Hussien, A. M.,
Fahmy, M. A.,
Elesawi, I. E.,
Salem, H. M.,
Mohammed, D. M.,
Abd El-Mageed, T. A.,
Ahmed, A. E.,
Mosa, W. F. A.,
El-Tarabily, M. K.,
AbuQamar, S. F.,
El-Tarabily, K. A.:
Chitosan, derivatives, and its nanoparticles: preparation, physicochemical properties, biological activities, and biomedical applications - A comprehensive review.
Int. J. Biol. Macromol. 313, 1-41, (article identifier: 142832), 2025.
Lorusso, D.,
Xiang, Y.,
Hasegawa, K.,
Scambia, G.,
Leiva, M.,
Ramos-Elias, P.,
Acevedo, A.,
Sukhin, V.,
Cloven, N.,
Santana Gomes, A. J. P. d.,
Contreras Mejía, F.,
Reiss, A.,
Ayhan, A.,
Lee, J. Y.,
Saevets, V.,
Zagouri, F.,
Gilbert, L.,
Sehouli, J.,
Tharavichitkul, E.,
Lindemann, K.,
Lazzari, R.,
Chang, C. L.,
Lampé, R.,
Zhu, H.,
Oaknin, A.,
Christiaens, M.,
Polterauer, S.,
Usami, T.,
Li, K.,
Yamada, K.,
Toker, S.,
Keefe, S. M.,
Pignata, S.,
Duska, L. R.,
ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators:
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet. 403 (10434), 1341-1350, 2024.
NCD Risk Factor Collaboration (NCD-RisC),
Semánová, C.:
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
Lancet. 403 (10431), 1027-1050, 2024.
GBD 2021 Stroke Risk Factor Collaborators:
Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Lancet Neurol. 23 (10), 973-1003, 2024.
GBD 2021 Diseases and Injuries Collaborators:
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Lancet. 403 (10440), 2133-2161, 2024.
GBD 2021 Fertility and Forecasting Collaborators:
Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
Lancet. 403 (10440), 2057-2099, 2024.
GBD 2021 Causes of Death Collaborators:
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Lancet. 403 (10440), 2100-2132, 2024.
